ESA achieves a new low reporting limit for lactose

ESA Laboratories, Inc., a Magellan Biosciences company, has announced that the reporting limit for the most widely used pharmaceutical surrogate, lactose, has been lowered to 0.5 ng per sample.

Since 1996, ESAL has been a leader in the field of surrogate monitoring continuously pushing the sensitivity lower using the technology of its parent company, ESA Biosciences. Using the ESA Coulochem^® III detector, a proprietary gold target electrode, and other advances in chromatography, the reporting limit for lactose in air has been lowered to 0.5 ng/filter-down from 2 ng in 2002 and 25 ng per filter in 1996.

According to ESAL's Laboratory Director, Pauline Lambert, ESAL's reporting limits for surrogate monitoring are the lowest available in the industry. A reporting limit of 0.5 ng for lactose is a real breakthrough. One of the wonders of modern medicine has been the development of powerful new pharmaceutical compounds. With these new potent drugs, the risks of exposure in the development and manufacturing processes are increasing; the need for monitoring containment is greater than ever.

Using ESA Bioscience's proprietary electrochemical technology, that includes the best in both amperometric and coulometric detectors, reporting limits for lactose (0.5 ng / filter), mannitol (1ng / filter), naproxen (0.25 ng / filter), and acetaminophen (0.5ng / filter) are the lowest available.